Telomere Shortening Clinical Trial
Official title:
Essai Bayésien de Phase I/II évaluant l'efficacité et la tolérance du Danazol Chez Les Patients Ayant Une Atteinte hématologique ou Pulmonaire sévère liée à Une téloméropathie - ANDROTELO
Constitutional mutations of genes involved in telomere repair and maintenance are responsible
for "telomeropathy" (" Congenital Dyskeratosis "). Attrition of telomeres promotes cell
senescence and genetic instability. The penetrance and severity of organ damage (pulmonary,
hematological, liver, and neurological) is variable, depending on the gene involved, the
generation concerned (anticipation phenomenon) and also environmental factors.
In cases of bone marrow failure, the only curative treatment is hematopoietic stem cell
transplant, often limited by pulmonary and / or hepatic involvement or the absence of a
suitable HLA match donor. The pulmonary phenotype is most often that of idiopathic pulmonary
fibrosis. In severe forms, a lung transplant is proposed in the absence of contraindications.
Anti-fibrotic treatments are not very effective or not evaluated. The observed decrease in
the vital capacity of these patients is 300 ml / year, abnormally high compared to idiopathic
forms. Evolution without transplant is in both situations rapidly unfavorable; the prognosis
after lung or marrow transplant is also worse than that of similar transplants without
telomeres disease.
Danazol has been used for over 4 decades in acquired and constitutional bone marrow failure
in the absence of a therapeutic alternative. In telomeropathy, retrospective data on small
cohorts indicate a haematological response rate of 60-70%. A prospective study in the United
States recently showed a haematological response at 1 year in 78% of cases (10 of 12
evaluable patients) with stabilization of vital capacity. Retrospective data (unpublished) on
patients treated in France have shown more side effects and more frequent treatment
interruptions and eventually weaker haematological response rate. This study aim to evaluate
the benefit of danazol at 12 months on the clinical response.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04638517 -
The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis
|
Phase 2 | |
| Completed |
NCT02844478 -
Stress-Busting Program and QoL, Bio-markers of Immunity/Stress and Cellular Aging
|
N/A | |
| Completed |
NCT04763525 -
Efficacy of Pythagorean Self-Awareness for Aging Biomarkers Improvement, in T2D Patients and Healthy Individuals.
|
N/A | |
| Active, not recruiting |
NCT02299245 -
Rosuvastatin Effect on Telomere-telomerase System in ACS
|
Phase 4 | |
| Recruiting |
NCT05508321 -
Nasal Brushing for the Diagnosis and Understanding of Telomeropathies
|
N/A | |
| Completed |
NCT03982589 -
Telomere Length in Relation to Acute Stress Response in Critical Care Patients
|
||
| Not yet recruiting |
NCT05978921 -
Physical Exercise in Patients With Schizophrenia
|
N/A | |
| Terminated |
NCT05715372 -
Genetic Evaluation and Modification of Lifestyles to Improve Female Life Expectancy
|
N/A | |
| Active, not recruiting |
NCT03286699 -
Lifestyle Change for Better Health
|
N/A | |
| Not yet recruiting |
NCT05598359 -
TA-65 and Aging Associated Microvascular Dysfunction
|
N/A | |
| Recruiting |
NCT06056375 -
Biological and Behavioral Outcomes of Community Nature Walks
|
Phase 1 | |
| Completed |
NCT02055456 -
Nandrolone Decanoate in the Treatment of Telomeropathies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04211714 -
Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure
|
Phase 1 | |
| Completed |
NCT03459053 -
CBART: The Reduction of Psychological and Physiological Stress in Women Undergoing IVF
|
N/A |